search
Back to results

Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia (RCC2)

Primary Purpose

Depression, Delirium, Seizures

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ketamine
Electroconvulsive Therapy
Sponsored by
Washington University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Depression focused on measuring Anesthesia, Electroconvulsive therapy, Delirium, Electroencephalography, Seizures, Depression, Ketamine, Etomidate, Physiological Effects of Drugs, Pharmacologic Actions, Confusion, Mental Disorders, Neurobehavioral Manifestations, Signs and Symptoms, Neurologic Manifestations, Cognitive Disorders

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Treatment resistant depression requiring outpatient ECT
  • Planned right unilateral ECT stimulation
  • English speaking
  • Able to provide written informed consent

Exclusion Criteria:

  • Known brain lesion or neurological illness that causes cognitive impairment
  • Schizophrenia
  • Schizoaffective disorder
  • Blindness or deafness or motor impediments that may impair performance for cognitive testing battery
  • Inadequate ECT seizure duration with etomidate

Sites / Locations

  • Washington University School of Medicine

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Sham Comparator

Arm Label

Etomidate + ECT

Ketamine + ECT

Ketamine alone

Arm Description

General anesthesia for ECT will be induced with etomidate, approximately 0.2 mg/kg (0.1-0.6 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.

General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.

General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, no ECT charge will be administered.

Outcomes

Primary Outcome Measures

Change in Cognitive Function During Recovery: Rate of Recovery
A cognitive test battery was administered at 0, 30, 60, 90, and 120 minutes following return of consciousness after general anesthesia on each treatment day (1-6). The data from each treatment day (1-6) were averaged for analyses. Cognition Test Battery: Psychomotor Vigilance Task (PVT) Digital Symbol Substitution Task (DSST) Motor Praxis Task (MP) Visual Object Learning Task (VOLT) Abstract Matching (AM) Rate of Recovery for this measure is defined as the time (in inverse hours) for participants to return to their baseline performance for each task.
Change in Cognitive Function During Recovery: Initial Decrement
A cognitive test battery was administered at 0, 30, 60, 90, and 120 minutes following return of consciousness after general anesthesia on each treatment day (1-6). The data from each treatment day (1-6) were averaged for analyses. Cognition Test Battery: Psychomotor Vigilance Task (PVT) Digital Symbol Substitution Task (DSST) Motor Praxis Task (MP) Visual Object Learning Task (VOLT) Abstract Matching (AM) Initial Decrement for this measure is defined as the difference between response times (in seconds) at baseline and t=0 for each task.

Secondary Outcome Measures

Delirium Incidence and Severity
Assessed using 3D Confusion Assessment Method (CAM). The groups/arms for this outcome are separated by anesthetic regimen; however, due to the crossover design of this study all participants are included in analyses for each group.
Suicidality
The groups/arms for this outcome are combined as a whole-group analysis due to the crossover design of this study, as pre-specified by the study protocol. Breaking up the analyses into the various arms of the study would change our scientific questions and approach. All participants included in analyses completed all treatments, the various arms for the study vary only in the order in which participants received each treatment. These data show the change in suicidality from baseline to treatment 6 based on the Scale of Suicide Ideation. The measure completed was the Scale of Suicide Ideation. For this study, participants completed the following questions of the questionnaire: wish to live (0 Moderate to Strong, 1 Weak, 2 None) wish to die (0 None, 1 Weak, 2 Moderate to Strong) The total scores range from 0-4. Lower scores indicate high suicide ideation, and high scores indicate low suicide ideation.
ECT Seizure Duration
Duration (in seconds) of seizure induced by ECT treatment
ECT Electrical Dose
The electrical dose necessary for seizure induction is determined during a dose-charge titration session prior to participant randomization and session 1. These results report the average electrical dose across all participants for the first treatment session during Treatment Week 1. The range for these data is 0 - 100% electrical charge.
Subjective Assessment of Whether ECT Was Performed, Determined by Asking the Patient.
To assess patient blinding of treatment performed, the patient will be asked: "Based on how you feel, did you have ECT today?" Results indicate participants correctly answering the subjective assessment.
Change in Mood Assessed Using the Mood Self-Assessment Manikin
Mood Self-Assessment Manikin (SAM) Scale: 1 (very unpleasant) - 9 (very pleasant). The groups/arms for this outcome are combined as a whole-group analysis due to the Crossover design of this study, as pre-specified by the study protocol. Breaking up the analyses into the various arms of the study would change our scientific questions and approach. Further, any statistical analyses would be underpowered due to low participant numbers in each arm. Thus, the results are combined and reported as a whole group analysis. All participants included in analyses completed all treatments included in the study, the various arms for the study vary only in the order in which participants received each treatment. These data show the change in mood from baseline to treatment 6 based on the SAM. Additionally, data collected at baseline are not dependent on the study group/arm.
Average Change in Mood Based on the Depression PROMIS-CAT
PROMIS-CAT (Patient Reported Outcomes Measurement Information System-Computer Adaptive Testing) for depression The groups/arms for this outcome are combined as a whole-group analysis due to the Crossover design of this study, as pre-specified by the study protocol. Breaking up the analyses into the various arms of the study would change our scientific questions and approach. Further, any statistical analyses would be underpowered due to low participant numbers in each arm. Thus, the results are combined and reported as a whole group analysis. All participants included in analyses completed all treatments included in the study, the various arms for the study vary only in the order in which participants received each treatment. These data show the change in mood from baseline to treatment 6 based on the PROMIS-CAT. Additionally, data collected at baseline are not dependent on the study group/arm.
Change in Delta Band (0.5-4 Hz) Relative Power in the Scale EEG During Recovery
High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the delta band over the sum of total power between 0.5 - 70Hz.
Change in Theta Band (4-8 Hz) Relative Power in the Scalp EEG During Recovery
High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the theta band over the sum of total power between 0.5 - 70Hz.
Change in Alpha Band (8-13 Hz) Power in the Scalp EEG During Recovery
High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the alpha band over the sum of total power between 0.5 - 70Hz.
Change in Beta Band (13-20 Hz) Relative Power in the Scalp EEG During Recovery
High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the beta band over the sum of total power between 0.5 - 70Hz.
Change in Anterior-Posterior Functional Connectivity in the Scalp During Recovery
High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the coherence measure, which is used for tracking changes in anterior-posterior functional connectivity. Coherence is a measure of synchronization between two signals which is used to measure anterior-posterior functional connectivity. Coherence is a unitless measure between 0 and 1. High coherence between time-series of two neural populations reflects higher efficiency in communication between those populations and therefore stronger functional connectivity.
Change in Anterior-Posterior Phase-lag in the Scalp EEG During Recovery
High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Phase-lag was assessed using the Phase-Lag Index (PLI), a measure ranging from 0 - 1. A consistent phase-lag between two tim-series results in a PLI of 1. A time-series without coupling results in a PLI near or equaling 0. Results show the difference in anterior-posterior PLI between baseline and post-ECT.
Change in EEG Entropy in the Scalp EEG During Recovery
High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as permutation entropy (PE) measures in posterior regions, which we are using to track changes in scalp EEG entropy. Permutation Entropy (PE) is a measure that is used to quantify the complexity of time series signals. It is a unitless measure between 0 and 1. Lower the PE represents a more regular and more deterministic time series while higher PE represents a more complex time series.

Full Information

First Posted
April 30, 2016
Last Updated
June 25, 2021
Sponsor
Washington University School of Medicine
Collaborators
James S McDonnell Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT02761330
Brief Title
Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia
Acronym
RCC2
Official Title
Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia Reconstitution of Consciousness and Cognition (Phase 2)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
April 2016 (Actual)
Primary Completion Date
September 11, 2019 (Actual)
Study Completion Date
September 11, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Washington University School of Medicine
Collaborators
James S McDonnell Foundation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is geared toward characterizing the recovery of brain activity and cognitive function following treatments of electroconvulsive therapy and ketamine general anesthesia.
Detailed Description
Seizures are often associated with loss of consciousness, possibly through effects on sub-cortical arousal systems, disruption of cortical-subcortical interactions, and ultimately through depressed neocortical function. Furthermore, people are often confused in the post-ictal state even when consciousness returns after a seizure. Disrupted cognitive function during the postictal phase has not been fully characterized but presents short and long-term implications. Many experience an acute disorder of attention, consciousness, and cognition, referred to as delirium. Memory deficits are also common. The neurobiology for these phenomena are incomplete and challenging to test, as seizures are typically sporadic and vary in intensity and character. In contrast, the setting of electroconvulsive therapy (ECT) provides the opportunity to study the reconstitution of consciousness and cognition following seizures in an elective and predictable context. There is no standard agent used to induce general anesthesia during ECT. Ketamine is receiving greater attention as an infusion for treating depression and for its potential benefits on improving ECT efficacy and expediting cognitive recovery. Further data are needed to determine whether ketamine may improve recovery of cognitive function relative to etomidate, a commonly used anesthetic for general anesthesia during ECT. The investigators will evaluate the cognition function and electroencephalographic patterns that accompany the recovery from ECT and general anesthesia. Twenty patients with refractory depression will be randomized in this interventional single-blinded randomized crossover trial. Each patient will complete seven study visits. The first visit will be conducted during the dose-charge titration ECT treatment with etomidate anesthesia. After this session, patients will be randomized to three sessions each week for two weeks (six treatments total). Over the first week patients will be randomized in order for three treatment arms: (1) etomidate general anesthesia and ECT, (2) ketamine general anesthesia and ECT, and (3) ketamine alone. Patients will be blinded to the treatment arm for each session. Baseline and post-treatment measurements of cognition and ECT will be acquired on each of the six treatment sessions. Patients that agree will have a MRI.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression, Delirium, Seizures, Cognitive Disorders
Keywords
Anesthesia, Electroconvulsive therapy, Delirium, Electroencephalography, Seizures, Depression, Ketamine, Etomidate, Physiological Effects of Drugs, Pharmacologic Actions, Confusion, Mental Disorders, Neurobehavioral Manifestations, Signs and Symptoms, Neurologic Manifestations, Cognitive Disorders

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Etomidate + ECT
Arm Type
Active Comparator
Arm Description
General anesthesia for ECT will be induced with etomidate, approximately 0.2 mg/kg (0.1-0.6 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
Arm Title
Ketamine + ECT
Arm Type
Experimental
Arm Description
General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
Arm Title
Ketamine alone
Arm Type
Sham Comparator
Arm Description
General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, no ECT charge will be administered.
Intervention Type
Drug
Intervention Name(s)
Ketamine
Intervention Description
Ketamine will be used to induce general anesthesia with or without subsequent ECT. Within a single patient, the dose will remain consistent throughout the study and is estimated to be 2 mg/kg.
Intervention Type
Procedure
Intervention Name(s)
Electroconvulsive Therapy
Other Intervention Name(s)
ECT
Intervention Description
Dose of the ECT charge will be determined during titration session prior to randomization.
Primary Outcome Measure Information:
Title
Change in Cognitive Function During Recovery: Rate of Recovery
Description
A cognitive test battery was administered at 0, 30, 60, 90, and 120 minutes following return of consciousness after general anesthesia on each treatment day (1-6). The data from each treatment day (1-6) were averaged for analyses. Cognition Test Battery: Psychomotor Vigilance Task (PVT) Digital Symbol Substitution Task (DSST) Motor Praxis Task (MP) Visual Object Learning Task (VOLT) Abstract Matching (AM) Rate of Recovery for this measure is defined as the time (in inverse hours) for participants to return to their baseline performance for each task.
Time Frame
0, 30, 60, 90, 120 minutes following return of consciousness, assessed on treatment days 1-6.
Title
Change in Cognitive Function During Recovery: Initial Decrement
Description
A cognitive test battery was administered at 0, 30, 60, 90, and 120 minutes following return of consciousness after general anesthesia on each treatment day (1-6). The data from each treatment day (1-6) were averaged for analyses. Cognition Test Battery: Psychomotor Vigilance Task (PVT) Digital Symbol Substitution Task (DSST) Motor Praxis Task (MP) Visual Object Learning Task (VOLT) Abstract Matching (AM) Initial Decrement for this measure is defined as the difference between response times (in seconds) at baseline and t=0 for each task.
Time Frame
0, 30, 60, 90, 120 minutes following return of consciousness, assessed on treatment days 1-6.
Secondary Outcome Measure Information:
Title
Delirium Incidence and Severity
Description
Assessed using 3D Confusion Assessment Method (CAM). The groups/arms for this outcome are separated by anesthetic regimen; however, due to the crossover design of this study all participants are included in analyses for each group.
Time Frame
Immediately following return of consciousness (t=0) during treatment days 1-6.
Title
Suicidality
Description
The groups/arms for this outcome are combined as a whole-group analysis due to the crossover design of this study, as pre-specified by the study protocol. Breaking up the analyses into the various arms of the study would change our scientific questions and approach. All participants included in analyses completed all treatments, the various arms for the study vary only in the order in which participants received each treatment. These data show the change in suicidality from baseline to treatment 6 based on the Scale of Suicide Ideation. The measure completed was the Scale of Suicide Ideation. For this study, participants completed the following questions of the questionnaire: wish to live (0 Moderate to Strong, 1 Weak, 2 None) wish to die (0 None, 1 Weak, 2 Moderate to Strong) The total scores range from 0-4. Lower scores indicate high suicide ideation, and high scores indicate low suicide ideation.
Time Frame
assessed at baseline on treatment days 1-6.
Title
ECT Seizure Duration
Description
Duration (in seconds) of seizure induced by ECT treatment
Time Frame
up to days 1-6
Title
ECT Electrical Dose
Description
The electrical dose necessary for seizure induction is determined during a dose-charge titration session prior to participant randomization and session 1. These results report the average electrical dose across all participants for the first treatment session during Treatment Week 1. The range for these data is 0 - 100% electrical charge.
Time Frame
First ECT treatment session during Treatment Week 1
Title
Subjective Assessment of Whether ECT Was Performed, Determined by Asking the Patient.
Description
To assess patient blinding of treatment performed, the patient will be asked: "Based on how you feel, did you have ECT today?" Results indicate participants correctly answering the subjective assessment.
Time Frame
Assessed at 120 minutes after return of responsiveness on treatment days 1-6
Title
Change in Mood Assessed Using the Mood Self-Assessment Manikin
Description
Mood Self-Assessment Manikin (SAM) Scale: 1 (very unpleasant) - 9 (very pleasant). The groups/arms for this outcome are combined as a whole-group analysis due to the Crossover design of this study, as pre-specified by the study protocol. Breaking up the analyses into the various arms of the study would change our scientific questions and approach. Further, any statistical analyses would be underpowered due to low participant numbers in each arm. Thus, the results are combined and reported as a whole group analysis. All participants included in analyses completed all treatments included in the study, the various arms for the study vary only in the order in which participants received each treatment. These data show the change in mood from baseline to treatment 6 based on the SAM. Additionally, data collected at baseline are not dependent on the study group/arm.
Time Frame
baseline and 120 minutes after return of responsiveness, assessed on treatment days 1-6
Title
Average Change in Mood Based on the Depression PROMIS-CAT
Description
PROMIS-CAT (Patient Reported Outcomes Measurement Information System-Computer Adaptive Testing) for depression The groups/arms for this outcome are combined as a whole-group analysis due to the Crossover design of this study, as pre-specified by the study protocol. Breaking up the analyses into the various arms of the study would change our scientific questions and approach. Further, any statistical analyses would be underpowered due to low participant numbers in each arm. Thus, the results are combined and reported as a whole group analysis. All participants included in analyses completed all treatments included in the study, the various arms for the study vary only in the order in which participants received each treatment. These data show the change in mood from baseline to treatment 6 based on the PROMIS-CAT. Additionally, data collected at baseline are not dependent on the study group/arm.
Time Frame
baseline and 120 minutes after return of responsiveness, assessed on treatment days 1-6
Title
Change in Delta Band (0.5-4 Hz) Relative Power in the Scale EEG During Recovery
Description
High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the delta band over the sum of total power between 0.5 - 70Hz.
Time Frame
baseline, post-ECT from 0-120 minutes
Title
Change in Theta Band (4-8 Hz) Relative Power in the Scalp EEG During Recovery
Description
High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the theta band over the sum of total power between 0.5 - 70Hz.
Time Frame
baseline, post-ECT from 0-120 minutes
Title
Change in Alpha Band (8-13 Hz) Power in the Scalp EEG During Recovery
Description
High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the alpha band over the sum of total power between 0.5 - 70Hz.
Time Frame
baseline, post-ECT from 0-120 minutes
Title
Change in Beta Band (13-20 Hz) Relative Power in the Scalp EEG During Recovery
Description
High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the percent of total power in the beta band over the sum of total power between 0.5 - 70Hz.
Time Frame
baseline, post-ECT from 0-120 minutes
Title
Change in Anterior-Posterior Functional Connectivity in the Scalp During Recovery
Description
High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as the coherence measure, which is used for tracking changes in anterior-posterior functional connectivity. Coherence is a measure of synchronization between two signals which is used to measure anterior-posterior functional connectivity. Coherence is a unitless measure between 0 and 1. High coherence between time-series of two neural populations reflects higher efficiency in communication between those populations and therefore stronger functional connectivity.
Time Frame
baseline, post-ECT from 0-120 minutes
Title
Change in Anterior-Posterior Phase-lag in the Scalp EEG During Recovery
Description
High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Phase-lag was assessed using the Phase-Lag Index (PLI), a measure ranging from 0 - 1. A consistent phase-lag between two tim-series results in a PLI of 1. A time-series without coupling results in a PLI near or equaling 0. Results show the difference in anterior-posterior PLI between baseline and post-ECT.
Time Frame
baseline, post-ECT from 0 -120 minutes
Title
Change in EEG Entropy in the Scalp EEG During Recovery
Description
High-density EEG collected during 5-minute epochs of eyes-closed quiet resting at baseline and post-ECT. Results are reported as permutation entropy (PE) measures in posterior regions, which we are using to track changes in scalp EEG entropy. Permutation Entropy (PE) is a measure that is used to quantify the complexity of time series signals. It is a unitless measure between 0 and 1. Lower the PE represents a more regular and more deterministic time series while higher PE represents a more complex time series.
Time Frame
baseline, Post-ECT from 0 -120 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Treatment resistant depression requiring outpatient ECT Planned right unilateral ECT stimulation English speaking Able to provide written informed consent Exclusion Criteria: Known brain lesion or neurological illness that causes cognitive impairment Schizophrenia Schizoaffective disorder Blindness or deafness or motor impediments that may impair performance for cognitive testing battery Inadequate ECT seizure duration with etomidate
Facility Information:
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33652270
Citation
Hickman LB, Kafashan M, Labonte AK, Chan CW, Huels ER, Guay CS, Guan MJ, Ching S, Lenze EJ, Farber NB, Avidan MS, Hogan RE, Palanca BJA. Postictal generalized electroencephalographic suppression following electroconvulsive therapy: Temporal characteristics and impact of anesthetic regimen. Clin Neurophysiol. 2021 Apr;132(4):977-983. doi: 10.1016/j.clinph.2020.12.018. Epub 2021 Jan 28.
Results Reference
derived
PubMed Identifier
33137572
Citation
Hickman LB, Hogan RE, Labonte AK, Kafashan M, Chan CW, Huels ER, Ching S, Lenze EJ, Maccotta L, Eisenman LN, Keith Day B, Farber NB, Avidan MS, Palanca BJA. Voltage-based automated detection of postictal generalized electroencephalographic suppression: Algorithm development and validation. Clin Neurophysiol. 2020 Dec;131(12):2817-2825. doi: 10.1016/j.clinph.2020.08.015. Epub 2020 Sep 11.
Results Reference
derived
PubMed Identifier
29867602
Citation
Palanca BJA, Maybrier HR, Mickle AM, Farber NB, Hogan RE, Trammel ER, Spencer JW, Bohnenkamp DD, Wildes TS, Ching S, Lenze E, Basner M, Kelz MB, Avidan MS. Cognitive and Neurophysiological Recovery Following Electroconvulsive Therapy: A Study Protocol. Front Psychiatry. 2018 May 14;9:171. doi: 10.3389/fpsyt.2018.00171. eCollection 2018.
Results Reference
derived

Learn more about this trial

Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia

We'll reach out to this number within 24 hrs